Divi Labs Q4 profit up 81% to ₹883 cr; revenue grows 46%
ADVERTISEMENT
Pharmaceuticals company Divi's Laboratories has reported a standalone net profit of ₹883 crore, a record growth of 81% as compared to ₹488 crore profit during the same period last year.
The homegrown pharma major's revenue rose 46% to ₹2,546 crore in Q4 FY22 as compared to ₹1,741 crore during Q4 FY21, the company's stock exchange filing shows.
The expanse for the quarter on a standalone basis increased to ₹183 crore vs 164 crore during the quarter ending in March 2021.
For the fiscal year ending March 31, 2022, Divi's Laboratories earned a consolidated revenue of ₹9,074 crore against ₹7,032 crore during the previous year, reflecting a growth of 29%.
Profit before tax for the current year grew by 38% to ₹3,684 crore against a PBT of ₹2,666 crore for the previous year. Profit for the year amounted to ₹2,960 crore against a profit after tax (PAT) of ₹1,984 crore the last year, reflecting a growth of 49%.
January 2026
Netflix, which has been in India for a decade, has successfully struck a balance between high-class premium content and pricing that attracts a range of customers. Find out how the U.S. streaming giant evolved in India, plus an exclusive interview with CEO Ted Sarandos. Also read about the Best Investments for 2026, and how rising growth and easing inflation will come in handy for finance minister Nirmala Sitharaman as she prepares Budget 2026.
The Hyderabad-headquartered company's forex gains for the quarter ending March 31, 2022, stand at ₹29 crore against ₹3 crore during the same quarter last year.
Divi Lab board has recommended a dividend of ₹30 per share of face value ₹2 each i.e., 1,500% for the financial year 2021-22, subject to the approval of members at the ensuing annual general meeting.
During the year 2021-22, the company has capitalised assets valuing ₹934.5 crore, while capital WIP (work in progress) at the year-end amounted to ₹469.9 crore.
The earnings per share (of ₹2 each) stood at ₹33.70 for the March 2022 quarter vs ₹33.99 for the previous quarter of the fiscal year.
Divi’s is the leading manufacturer of APIs (active pharmaceuticals ingredients), intermediates and registered starting materials offering high-quality products with the highest level of compliance and integrity to over 95 countries.
Amid the announcement of the financial result, the company's share is trading 0.78% or ₹33.70 up at ₹4,337.15 on the National Stock Exchange on Monday. The stock rose 3.01% in the past five days, while it dipped 1.54% in the past month. In the six-month or year-to-date period, the stock has given 8.84% and 6.65% of its value.